• Twitter CVCT Forum
  • CVCT Forum LinkedIn
  • CVCT Forum YouTube
IMG_1255.JPG
C (2).png

18th Global Cardio

ascular

Clinical Trialists Forum

Save%20the%20Date%20Text%20CVCT%202021_e

2 - 4 December 2021

CardioVascular, CardioRenal and Cardiometabolic medicine is increasingly evidence-based. Every year brings a series of landmark, game changing trials. These are presented at major meetings "Late Breaking Clinical Trials sessions", which last only 10 minutes, followed by 5 mins discussion. Sometimes only the main results are published simultaneously or short after the event. Limited discussion among commentators may occur on social media.

 

CVCT is the only global meeting where hours are spent discussing individual trials, among the most authoritative stakeholders.

 

* CVCT is a unique think tank forum aiming at discussing the critical latest CardioVascular, CardioRenal and Cardiometabolic trials, individually and in context

* Discussion includes understanding trial rationale, design issues, trial conduct and operational issues, statistical methodology and interpretation, clinical meaning, approvability by major regulatory agencies, valuation by payers, implementation into practice guidelines, in real life by physicians.

* CVCT is unique in that it assembles the key global experts from multiple backgrounds.

* Academy trialists and Primary Investigators of major trials

* Pharma and Device Industry R&D and CROs.

* Regulatory agencies (FDA,EMA, MHRA, etc...)

* Major journal editors(NEJM, The Lancet, JAMA, Circ, JACC, EHJ…)

* Major research organisations (NHLBI, EC, Inserm..)

* Payers (CMS, NICE, HTA organisations)

* Lawyers

* Patients. Login and listen, interrogate and eMeet with trials experts

CVCT2020

On-Demand :

 The CVCT 2020 On-demand contentent is now LIVE ! If you've registered to attend CVCT 2020, please use your login details, otherwise register now to access !

 

Scientific Program

DEC 3 -7, 2020

All times in the program are Central European Time (CET)

why attend

Highlights

 
 

Founder & chairman

Zannad_photo.jpg

Faiez Zannad

NANCY, FRA

MD, Cardiologist, PhD in clinical pharmacology (Université de Lorraine, Nancy, Université
Claude Bernard, Lyon, France and Oxford MRC, UK). Emeritus Professor of Therapeutics at the Université of Lorraine, Past Director Division of
Heart Failure and Hypertension, and of the Inserm Clinical Investigation Center at Institut
Lorrain du Coeur et des Vaisseaux, Nancy, France. Visiting Professor at the Brigham &
Women’s hospital, Harvard Medical School, USA, as a Eugene Braunwald Scolar. (2019),
Trophées des Etoiles of the French Ministry of Research (2019), ESC-HFA Lifetime Achievement Award (2017), ESH Paul Milliez Award (2014).He has served as Chairman of the French Society of Hypertension, Chairman of the European Society of Cardiology (ESC) Working Group on Pharmacology and Drug Therapy, and as a board member of the Heart Failure Association (HFA) of the ESC. He is Clinical Pharmacology Section Editor of ESC Texbook.

Co-chairman

Bertram Pitt

ANN ARBOR, USA

Bertram Pitt is a professor of medicine emeritus at the University of Michigan, School of Medicine. Dr Pitt obtained his MD degree from the University of Basel in Switzerland. He completed a fellowship in cardiology at the Johns Hopkins University School of Medicine and remained on the faculty until he left to direct the division of cardiology at the University of Michigan. He is currently chairman of the steering committee of the NHLBI TOPCAT trial.

Bertram-PITT_medium.jpg

Interventional | iCVCT

Co-chair persons

Mehran_photo.jpg

Roxana Mehran

NEW YORK, USA

Roxana Mehran is a Professor of Medicine, Cardiology, and Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai, and Director of the Center for Interventional Cardiovascular Research and Clinical Trials at Mount Sinai. She is a founder and Chief Scientific Officer of the Cardiovascular Research Foundation (CRF) and recently founded Women as One.

Michael Gibson

BOSTON, USA

Dr. Michael Gibson is an interventional cardiologist, cardiovascular researcher and educator.  Gibson founded and has led his own Academic Research Organization (PERFUSE) for over 25 years, and his work has been presented in over 1000 manuscripts, abstracts, & trial summaries. PERFUSE offers a full line of trial management, social media portals, CEC, DSMB and core lab services for phase 1-4 trials worldwide. In November 2012, Gibson was appointed Professor of Medicine at Harvard Medical School. Gibson is also the Chairman of the Board for the WikiDoc Foundation; the world’s largest, free, living textbook of medicine viewed over 400,000 times daily. As Principal Investigator, Dr. Gibson is responsible for the overall scientific leadership throughout the trial period. He works closely with the study personnel on protocol development, case report development, FDA meeting attendance, EC/SC/DSMB committee assembly, overall project management, development of the statistical analysis plan, and manuscript preparation.

Gibson_photo.jpg

Global CVCT Forum

FORUM

Partner Learned

Societies

(NHLBI, EC, Inserm..)

Academia

Regulatory

Agencies

(FDA,EMA, MHRA, etc...)

Patient

Representatives

(CMS, NICE, HTA organisations)

Payers

Industry

CROs

Young Fellows

Scientific Press

Statisticians

(NEJM, The Lancet, JAMA, Circ, JACC, EHJ…)

Global CVCT Forum is usually held in Washington, USA. Due to this year's events, 17th Global CVCT Forum will be exceptionnaly taking place as a

unique DIGITAL LIVE experience with highly interactional program, a large number of stakeholders and LIVE DISCUSSION on the most important topics.

Join us now !

EXPAND OVER
INCLUDING
INVOLVING

05

45

310

DAYS
SESSIONS
SPEAKERS
 

Submit an abstract

Submission opening: June 5, 2020

Submission closing (extended): November 13, 2020

Poster Presentations

We invite you to consider presenting a Poster at CVCT.

Previously published abstracts cannot be submitted unless there is significant new data.

Poster presentations describing original cardiovascular clinical trial work in the following areas are welcome:

  • Arrhythmia Trials

  • Atherosclerosis Trials

  • Baseline Characteristics of Ongoing Trials

  • Biomarkers and Imaging, Precision Medicine Trials

  • CV Outcome Trials in Diabetes

  • CV Protection in CKD trials

  • Device Trials

  • Endpoints Definitions

  • Ethical Issues

  • eTrials and use of Digital Technology in Trials

  • Health Economics in Trials

  • Heart Failure Trials

  • Implementation Issues

  • Interventional Cardiology Trials

  • Mechanistic Substudies

  • Meta-analyses

  • Methodology, Design and Statistics

  • Regulatory Approval

  • Reimbursement Issues

  • Thrombosis Trials

At least one of the abstract authors must be registered for the conference. All questions pertaining to the CVCT poster submission should be directed to cvct@overcome.fr

Abstracts Formats

The abstract must not exceed 500 words, and should be organized as follows:

  • Title

  • Author(s) + Affiliations

  • Background/Aims

  • Method

  • Results

  • Conclusion

Authors full names and affiliations must be specified; surnames should be in capital letters.

All abstracts should be submitted in English.

PLEASE NOTE

  • A maximum of TWO abstracts from a presenter will be considered.

  • The Scientific Committee will decide on the suitability of each abstract.

CVCT - Jason Dixson Photography - 124145
 
Bureau moderne

CVCT Webinar Series

ONLINE

CVCT Webinar Series are a unique way to learn from major stakeholders and key experts, engage with them and continue the discussion on the subjects that matter, all year long. 

Find the next available dates and register to take part in the next CVCT Webinar